



Irish Blood Transfusion Service

Seirbhís Fuilaidriúcháin na hÉireann

Document Detail

Type: PMF IBTS SPEC
Document No.: IBTS/PMF/SPEC/0203[2]
Title: **WHOLE BLOOD SUITABLE FOR NEONATAL USE**
Owner: 1066 KATE FITZGERALD
Status: CURRENT
Effective Date: 06-Aug-2015
Expiration Date:

Review

Review: IBTS PMF REVIEW

<u>Level</u>	<u>Owner Role</u>	<u>Actor</u>	<u>Sign-off By</u>
1	DIRECTOR OF QUALITY	MARIE O'CONNELL	MARIE O'CONNELL
1	LABS HEAD OF PROCESSING IBTS	BERNIE QUIRKE	BERNIE QUIRKE
1	QUALITY MANAGER MRTC	COLIN JOHNS	COLIN JOHNS
1	NATIONAL MEDICAL DIRECTOR	WILLIAM MURPHY	WILLIAM MURPHY

Change Orders

Changes as described on Change Order: Change Order No.

Change Orders - Incorporated

Changes as described on Change Order: Change Order No.
IBTS/CO/0329/15

IRISH BLOOD TRANSFUSION SERVICE

PRODUCT MASTER FILE

Title: Whole Blood Suitable for Neonatal Use

Name of Products: WHOLE BLOOD, Suitable for Neonatal Use for 5 days after Date Drawn / WHOLE BLOOD Suitable for Neonatal Use, Irradiated

E Progesa Codabar Component Codes : 03151 / 39355

E progesa ISBT – 128 Component Codes : C6468V00 / C5584V00

General Description: The unit of blood is collected into CPD (Citrate, Phosphate Dextrose). The majority of leucocytes in the donation are removed by filtration. The selected donors meet the additional criteria for neonatal use.

General Specification:

Parameter	Quality Requirement	Frequency of Control
Volume	450-525 mL	100%
Haematocrit	≥ 0.35	$\geq 1\%$
Haemoglobin	≥ 45 g/unit	$\geq 1\%$
Leucocyte Content	$< 1 \times 10^6$ / unit	1 per week
Haemolysis at end of shelf life	$< 0.8\%$ of red cell mass	4 per annum (including irradiated units)
ABO Agglutinins	No HighTitre Anti-A or Anti-B	100%
CMV	CMV ab negative	100%

Labelling: See Appendix I

Storage: Whole Blood, Suitable for Neonatal Use for 5 days after Date Drawn / WHOLE BLOOD Suitable for Neonatal Use, Irradiated should be stored at $4^{\circ}\text{C} \pm 2^{\circ}\text{C}$

Irradiation: Whole Blood, Suitable for Neonatal Use for 5 days after Date Drawn should be irradiated before transfusion provided this does not unduly delay the transfusion. Post irradiation the component code changes to 39355/C5584V00. The irradiated product should be used within 24 hours. It **must** be irradiated prior to transfusion where the neonate has had a previous intrauterine transfusion.

Transportation: The air temperature of transport containers for units of Whole Blood, Suitable for Neonatal Use for 5 days after Date Drawn / WHOLE BLOOD Suitable for Neonatal Use, Irradiated should be maintained between 2°C and 10°C during transport from the Irish Blood Transfusion Service to the place where they are intended for use. Transport time under these conditions normally should not exceed 8 hours.

Indications for Use: Whole Blood, Suitable for Neonatal Use for 5 days after Date Drawn / WHOLE BLOOD Suitable for Neonatal Use, Irradiated, is suitable for exchange transfusion and is used to augment the oxygen delivery capacity of the blood where this is critically impaired.

Precautions in Use:

- Compatibility of this component with the intended recipient must be verified by suitable pre transfusion testing.
- Should be transfused through a standard 170 – 200 µm filter.
- No solution should be added to the bag or to the giving set.
- Components should be inspected visually for defects, leakage, abnormal colour or visible clots.
- Not recommended in:
 - various types of plasma intolerance.
 - repeated leucocyte antigen/antibody mediated reaction unresponsive to medication

Adverse Effects Include:

- Circulatory Overload.
- Thrombocytopenia
- Haemolytic transfusion reaction
- Non-haemolytic transfusion reaction (mainly chills, fever and urticaria).
The risk is reduced by leucodepletion
- Anaphylaxis

Pathogen transmission

- Despite careful donor selection and laboratory screening procedures, infections including Syphilis, Viral Hepatitis, HIV, HTLV 1 & 11 and other viruses and protozoa (e.g. malaria) may, in rare instances, occur.
- vCJD transmission
- Transmission of other pathogens that are not tested for or recognised.
- The risk of CMV transmission is reduced by leucocyte depletion.
- Acute sepsis due to bacterial contamination

- Metabolic upset

- Possible elevated potassium level in massive transfusions, especially where patient is hypothermic or acidotic or has impaired renal function.
- Citrate toxicity, especially in neonates and in patients with impaired hepatic function.
- Hypocalcaemia.
- Hypoglycaemia.
- Hypokalaemia.

- Immunological effects

- Alloimmunisation to HLA and red cell antigens.
- Graft vs Host Disease (GvHD) in immuno compromised recipients .The risk of GvHD is eliminated by irradiation
- Transfusion related Acute Lung injury (TRALI) by donor HLA/granulocyte antibodies.
- Post transfusion purpura (PTP).

- Iron overload

- In patients on chronic red cell transfusion support programmes.

Serious Adverse Reaction

Serious adverse reactions should be reported to:

National Haemovigilance Office
Irish Blood Transfusion Service
National Blood Centre
James's Street
Dublin 8

AND

Quality Assurance Manager
Irish Blood Transfusion Service

AT EITHER

National Blood Centre
James's Street
Dublin 8

OR

St Finbarr's Hospital
Douglas Road, Cork

APPENDIX I

E Progesa Codabar Component Code: 03151

E Progesa ISBT – 128 Component Code : C6468V00

Product Name

WHOLE BLOOD, suitable for Neonatal Use for 5 Days after Date Drawn

Shelf life

28 days

Labelling and Barcode:

(for illustration purposes only – barcodes not suitable for scanning – label not to scale)

WHOLE BLOOD, suitable for Neonatal Use for 5 days after Date Drawn

Store at 4°C ± 2°C

Drawn 23 July 2015

490 ml

C6468V00

Rh D Positive

CMV Antibody Negative

Expiry 20 Aug 2015 23:59

C- c+ E- e+ K- HbS-Neg

03151

Expiry 20/08/2015

O Pos

This component must not be used if there are visible signs of deterioration. This component may transmit infection.

Must be administered using a suitable transfusion set incorporating a 170 - 200 µm filter. Collected into 65 ml of CPD anticoagulant containing, in mmol/l:

Citric Acid 16, Sodium Citrate 89, Sodium dihydrogen phosphate 16, Glucose 129, Total Na Concentration 284

APPENDIX I

E Progesa Codabar Component Code: 39355

E Progesa ISBT – 128 Component Code : C5584V00

Product Name

WHOLE BLOOD, Suitable for
Neonatal Use, Irradiated

Shelf life

24 hours

Labelling and Barcode:

(for illustration purposes only – barcodes not suitable for scanning – label not to scale)

IBTS ver 1.0

WHOLE BLOOD, Suitable for
Neonatal Use, Irradiated

Store at 4°C ± 2°C

015208

Drawn 27 July 2015

C5584V00

375 ml

0152100942

Expiry 29 July 2015 09:42

93999999999917796

C- c+ E- e+ K- HbS-Neg

39355

Expiry 29/07/2015

O Pos

CMV Antibody Negative
IRRADIATED (24 H)

O

Rh D Positive

This component must not be used if there are visible signs of deterioration. This component may transmit infection. Must be administered using a suitable transfusion set incorporating a 170 - 200 µm filter. Collected into 65 ml of CPD anticoagulant containing, in mmol/l: Citric Acid 16, Sodium Citrate 88, Sodium dihydrogen phosphate 18, Glucose 129. Total Na Concentration 284

N.B. Stated volume for illustration purposes only.